

Department of Health and Human Services MaineCare Services 11 State House Station Augusta, Maine 04333-0011 Tel.: (207) 287-2674; Fax: (207) 287-2675 TTY Users: Dial 711 (Maine Relay)

## DUR COMMITTEE AGENDA

Date: Tuesday, March 14, 2017

5:30PM to 8:30PM Time:

Augusta Armory, 179 Western Avenue, Augusta, ME Location:

- 1) Call to Order
- 2) Introductions of New Committee Members
- 3) MaineCare Updates
- **Public Comments**
- **Old Business** 
  - **Review of Minutes**
- Closed Session
  - **Drug Financial Information Review**
- 7) New Business (open session)
  - A. Retro-DUR
    - Data presentation: Co-prescribing of stimulants, benzodiazepines and "Z" drugs.
  - B. Retro-DUR
    - Introduce: Assessing the pattern of useage of long- acting stimulants, specifically looking at month than once a day dosing patterns and use among different age drugs, including pediatrics.
  - C. New Drug Review

Adyxin

Basaglar

Eucrisa

Rayaldee

Rubraca

Soliqua

Vemlidy

Yosprala

Zinplava

## D. FDA Safety Alerts

- General Anesthetic and Sedation Drugs: Drug Safety Communication New Warnings for Young Children and Pregnant Women
   <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm5331">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm5331</a>
   95.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery
- FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
   http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery
- FDA Releases Draft Guidance for Industry: "Considerations in Demonstrating Interchangeability With a Reference Product."-Drug Information Update
   <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM53713">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM53713</a>
   <a href="mailto:5.pdf?source=govdelivery&utm\_medium=email&utm\_source=govdelivery">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM53713</a>
   <a href="mailto:5.pdf?source=govdelivery&utm\_medium=email&utm\_source=govdelivery">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM53713</a>
   <a href="mailto:5.pdf?source=govdelivery&utm\_medium=email&utm\_source=govdelivery">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM53713</a>
   <a href="mailto:5.pdf?source=govdelivery&utm\_medium=email&utm\_source=govdelivery">http://www.fda.gov/downloads/Drugs/GuidanceSutm\_source=govdelivery</a>
- FDA confirms elevated levels of belladonna in certain homeopathic teething products
   http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm538684.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery
- Chlorhexidine Gluconate: Drug Safety Communication Rare But Serious Allergic Reactions
   http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm5395

   75.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery
- E. Next Meeting (Tuesday, June 27, 2017 from 5:30pm to 8:30pm)
- F. Adjournment: 8:30PM